This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +9.68% and -0.85%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of +7.69% and +3.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of 0% and 10.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of 31.08% and 30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma (STRO) delivered earnings and revenue surprises of -44.44% and 25.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -62.50% and 7.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.45% and 75.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 6.06% and 45.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Techne (TECH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 10.53% and 4.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Foghorn Therapeutics (FHTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of 26.19% and 3.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
by Zacks Equity Research
BeiGene (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
by Zacks Equity Research
Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 81.2% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
by Zacks Equity Research
Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 121.8% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Small Drug Stocks to Buy as Innovation Reaches Peak
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of 25% and 4.36%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?